Cargando…

Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine

Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis (Mtb), kills 5,000 people per day globally. Rapid development and spread of various multi drug-resistant strains of Mtb emphasize that an effective vaccine is still the most cost-effectives and efficient way of controlling...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Nancy, Garg, Saurabh, Vedi, Satish, Kunimoto, Dennis Y., Kumar, Rakesh, Agrawal, Babita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198790/
https://www.ncbi.nlm.nih.gov/pubmed/30386336
http://dx.doi.org/10.3389/fimmu.2018.02371
_version_ 1783365021558898688
author Gupta, Nancy
Garg, Saurabh
Vedi, Satish
Kunimoto, Dennis Y.
Kumar, Rakesh
Agrawal, Babita
author_facet Gupta, Nancy
Garg, Saurabh
Vedi, Satish
Kunimoto, Dennis Y.
Kumar, Rakesh
Agrawal, Babita
author_sort Gupta, Nancy
collection PubMed
description Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis (Mtb), kills 5,000 people per day globally. Rapid development and spread of various multi drug-resistant strains of Mtb emphasize that an effective vaccine is still the most cost-effectives and efficient way of controlling and eradicating TB. Bacillus Calmette-Guerin (BCG), the only licensed TB vaccine, still remains the most widely administered human vaccine, but is inefficient in protecting from pulmonary TB in adults. The protective immunity afforded by BCG is thought to wane with time and considered to last only through adolescent years. Heterologous boosting of BCG-primed immune responses using a subunit vaccine represents a promising vaccination approach to promote strong cellular responses against Mtb. In our earlier studies, we discovered lipopeptides of ESAT-6 antigen with strong potential as a subunit vaccine candidate. Here, we have investigated that potential as a booster to BCG vaccine in both a pre-exposure preventive vaccine and a post-exposure therapeutic vaccine setting. Surprisingly, our results demonstrated that boosting BCG with subunit vaccine shortly before Mtb challenge did not improve the BCG-primed immunity, whereas the subunit vaccine boost after Mtb challenge markedly improved the quantity and quality of effector T cell responses and significantly reduced Mtb load in lungs, liver and spleen in mice. These studies suggest that ESAT-6 lipopeptide-based subunit vaccine was ineffective in overcoming the apparent immunomodulation induced by BCG vaccine in Mtb uninfected mice, but upon infection, the subunit vaccine is effective in re-educating the protective immunity against Mtb infection. These important results have significant implications in the design and investigation of effective vaccine strategies and immunotherapeutic approaches for individuals who have been pre-immunized with BCG vaccine but still get infected with Mtb.
format Online
Article
Text
id pubmed-6198790
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61987902018-11-01 Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine Gupta, Nancy Garg, Saurabh Vedi, Satish Kunimoto, Dennis Y. Kumar, Rakesh Agrawal, Babita Front Immunol Immunology Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis (Mtb), kills 5,000 people per day globally. Rapid development and spread of various multi drug-resistant strains of Mtb emphasize that an effective vaccine is still the most cost-effectives and efficient way of controlling and eradicating TB. Bacillus Calmette-Guerin (BCG), the only licensed TB vaccine, still remains the most widely administered human vaccine, but is inefficient in protecting from pulmonary TB in adults. The protective immunity afforded by BCG is thought to wane with time and considered to last only through adolescent years. Heterologous boosting of BCG-primed immune responses using a subunit vaccine represents a promising vaccination approach to promote strong cellular responses against Mtb. In our earlier studies, we discovered lipopeptides of ESAT-6 antigen with strong potential as a subunit vaccine candidate. Here, we have investigated that potential as a booster to BCG vaccine in both a pre-exposure preventive vaccine and a post-exposure therapeutic vaccine setting. Surprisingly, our results demonstrated that boosting BCG with subunit vaccine shortly before Mtb challenge did not improve the BCG-primed immunity, whereas the subunit vaccine boost after Mtb challenge markedly improved the quantity and quality of effector T cell responses and significantly reduced Mtb load in lungs, liver and spleen in mice. These studies suggest that ESAT-6 lipopeptide-based subunit vaccine was ineffective in overcoming the apparent immunomodulation induced by BCG vaccine in Mtb uninfected mice, but upon infection, the subunit vaccine is effective in re-educating the protective immunity against Mtb infection. These important results have significant implications in the design and investigation of effective vaccine strategies and immunotherapeutic approaches for individuals who have been pre-immunized with BCG vaccine but still get infected with Mtb. Frontiers Media S.A. 2018-10-16 /pmc/articles/PMC6198790/ /pubmed/30386336 http://dx.doi.org/10.3389/fimmu.2018.02371 Text en Copyright © 2018 Gupta, Garg, Vedi, Kunimoto, Kumar and Agrawal. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Gupta, Nancy
Garg, Saurabh
Vedi, Satish
Kunimoto, Dennis Y.
Kumar, Rakesh
Agrawal, Babita
Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine
title Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine
title_full Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine
title_fullStr Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine
title_full_unstemmed Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine
title_short Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine
title_sort future path toward tb vaccine development: boosting bcg or re-educating by a new subunit vaccine
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198790/
https://www.ncbi.nlm.nih.gov/pubmed/30386336
http://dx.doi.org/10.3389/fimmu.2018.02371
work_keys_str_mv AT guptanancy futurepathtowardtbvaccinedevelopmentboostingbcgorreeducatingbyanewsubunitvaccine
AT gargsaurabh futurepathtowardtbvaccinedevelopmentboostingbcgorreeducatingbyanewsubunitvaccine
AT vedisatish futurepathtowardtbvaccinedevelopmentboostingbcgorreeducatingbyanewsubunitvaccine
AT kunimotodennisy futurepathtowardtbvaccinedevelopmentboostingbcgorreeducatingbyanewsubunitvaccine
AT kumarrakesh futurepathtowardtbvaccinedevelopmentboostingbcgorreeducatingbyanewsubunitvaccine
AT agrawalbabita futurepathtowardtbvaccinedevelopmentboostingbcgorreeducatingbyanewsubunitvaccine